AD/ADRD Clinical Trials Short Course
ID: 359856Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359856
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the AD/ADRD Clinical Trials Short Course aimed at enhancing the workforce skilled in Alzheimer's disease (AD) and AD-related dementias (ADRD) clinical trials. This initiative seeks to develop innovative short courses that will train the next generation of clinical trialists in advanced research skills pertinent to AD, frontotemporal dementia (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and mixed dementia, as well as interventions for treatment and prevention. While applications are not currently being solicited, potential applicants are encouraged to begin forming collaborations and project ideas in anticipation of the funding opportunity, which will utilize the R25 activity code. For further inquiries, interested parties can contact Laurie Ryan at the National Institute on Aging via email at ryanl@mail.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is September 1, 2025, with a closing date for applications expected by January 25, 2026, and an anticipated award date of December 1, 2026.

    Point(s) of Contact
    Laurie Ryan National Institute on Aging (NIA)
    (301) 496-9350
    ryanl@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting early- and late-stage clinical trials focused on Alzheimer's Disease (AD), Alzheimer's Disease-Related Dementias (ADRD), and age-related cognitive decline. This initiative seeks applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive, behavioral, and neuropsychiatric changes associated with these conditions, as well as studies to enhance trial design and methodologies. The funding opportunity, categorized under health-related discretionary grants, is intended for small businesses with expertise in aging research, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 5, 2025. For further inquiries, interested applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity for Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for early- and late-stage clinical trials focused on Alzheimer's Disease, Alzheimer's Disease-Related Dementias, and age-related cognitive decline. This initiative aims to invite applications that propose innovative pharmacological and non-pharmacological interventions to address cognitive and behavioral changes associated with these conditions, as well as to enhance trial design and methodologies. The NOFO is expected to be published in December 2024, with application due dates in March, June, and October of 2025, and an estimated award date set for December 1, 2025. Interested applicants are encouraged to prepare collaborative projects in advance, as there are no cost-sharing requirements associated with this grant opportunity.
    Notice of Intent to Publish a Notice of Funding Opportunity for Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer’s Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer’s disease (AD) and related dementias (ADRD). This initiative seeks applications for promising pharmacological and non-pharmacological strategies that may prevent, delay, or treat the symptoms of AD, utilizing the ACTC's trial coordination and management infrastructure. The NOFO is significant as it addresses a critical health challenge, and it is expected to be published in December 2024, with application due dates in March, June, and October of 2025. Interested applicants should prepare for the R01 activity code funding, with an estimated award date set for December 1, 2025.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Alzheimer's Clinical Trials Consortium (ACTC) aimed at developing and implementing multi-site Phase Ib to III clinical trials for interventions targeting Alzheimer's disease (AD) and related dementias (ADRD). This initiative seeks to foster collaborative efforts between applicants, the National Institute on Aging (NIA), and the ACTC network to test promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat symptoms associated with AD and ADRD. The funding opportunity, utilizing the R01 activity code, is particularly significant as it addresses the growing need for effective treatments for age-related cognitive decline. Interested small businesses are encouraged to prepare for application submission, with the estimated synopsis post date on August 1, 2025, and a closing date of October 5, 2025. For further inquiries, potential applicants can contact Laurie Ryan, Ph.D., at 301-496-9350 or via email at ryanl@mail.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Diversity in Aging Research (ADAR) through Undergraduate Education Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at advancing diversity in aging research through the establishment of a coordinating center under the Advancing Diversity in Aging Research (ADAR) initiative. This initiative seeks to develop and maintain a center that will support undergraduate education in aging research, with the NOFO expected to be a companion to the existing funding opportunity PAR-24-135. The anticipated funding amount for this cooperative agreement is $800,000, with one award expected to be made, and the application process is projected to open in May 2025, following a synopsis release in February 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of May 25, 2025, with awards expected to be made by March 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Deriving Common Data Elements from Real-World Data for Alzheimer�s Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at developing Common Data Elements (CDEs) for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) utilizing Real-World Data (RWD) from electronic health records and CMS claims. The objective is to enhance data harmonization and interoperability among disparate RWD systems, thereby facilitating more efficient research and faster production of real-world evidence. This funding opportunity, categorized as a cooperative agreement, has an estimated total program funding of $4 million, with a maximum award ceiling of $2.5 million, and is expected to result in one award. Interested applicants should prepare for the anticipated application due date in June 2024, following the expected publication of the NOFO in March 2024.
    NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25), aimed at enhancing training for a skilled workforce in Alzheimer's Disease (AD) and Alzheimer's Disease and Related Dementias (ADRD). This program seeks to support educational activities that provide intensive research experiences for recent baccalaureates, particularly those from underrepresented backgrounds, to prepare them for advanced degree programs or research careers in AD/ADRD. The NIH plans to commit $2,000,000 in FY 2027 and FY 2028 to fund up to five new awards annually, with a maximum project period of five years and direct costs of up to $400,000 per year. Interested applicants can find more information and application details at the provided link and should direct inquiries to grantsinfo@nih.gov, with applications due by May 26, 2027.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.